- Home
- MRAM vs VTYX Comparison
MRAM vs VTYX Comparison
Compare MRAM & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRAM
- VTYX
- Stock Information
- Founded
- MRAM 2008
- VTYX 2018
- Country
- MRAM United States
- VTYX United States
- Employees
- MRAM N/A
- VTYX N/A
- Industry
- MRAM Semiconductors
- VTYX Medicinal Chemicals and Botanical Products
- Sector
- MRAM Technology
- VTYX Health Care
- Exchange
- MRAM Nasdaq
- VTYX Nasdaq
- Market Cap
- MRAM 134.5M
- VTYX 154.9M
- IPO Year
- MRAM 2016
- VTYX 2021
- Fundamental
- Price
- MRAM $5.80
- VTYX $1.84
- Analyst Decision
- MRAM Strong Buy
- VTYX Buy
- Analyst Count
- MRAM 2
- VTYX 4
- Target Price
- MRAM $9.00
- VTYX $11.33
- AVG Volume (30 Days)
- MRAM 93.4K
- VTYX 1.9M
- Earning Date
- MRAM 02-26-2025
- VTYX 02-25-2025
- Dividend Yield
- MRAM N/A
- VTYX N/A
- EPS Growth
- MRAM N/A
- VTYX N/A
- EPS
- MRAM 0.07
- VTYX N/A
- Revenue
- MRAM $53,865,000.00
- VTYX N/A
- Revenue This Year
- MRAM N/A
- VTYX N/A
- Revenue Next Year
- MRAM $7.15
- VTYX N/A
- P/E Ratio
- MRAM $80.91
- VTYX N/A
- Revenue Growth
- MRAM N/A
- VTYX N/A
- 52 Week Low
- MRAM $4.89
- VTYX $1.67
- 52 Week High
- MRAM $9.39
- VTYX $11.48
- Technical
- Relative Strength Index (RSI)
- MRAM 35.09
- VTYX 39.45
- Support Level
- MRAM $6.11
- VTYX $1.91
- Resistance Level
- MRAM $6.30
- VTYX $2.15
- Average True Range (ATR)
- MRAM 0.23
- VTYX 0.16
- MACD
- MRAM -0.07
- VTYX -0.02
- Stochastic Oscillator
- MRAM 3.48
- VTYX 4.08
About MRAM Everspin Technologies Inc.
Everspin Technologies Inc is a provider of Magnetoresistive Random Access Memory (MRAM) products. Its portfolio of MRAM technologies, including Toggle MRAM and Spin-transfer Torque MRAM (STT-MRAM), delivers superior performance, persistence, and reliability in non-volatile memories that transform how mission-critical data is protected against power loss. The company derives revenue from the sale of MRAM-based products in discrete unit form, licenses of and royalties on MRAM and magnetic sensor technology, the sale of backend foundry services, and design services to third parties. It recognizes revenue in three primary geographic regions; North America; Europe, the Middle East, and Africa (EMEA); and Asia-Pacific (APAC).
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.